2024 Apr 3;17(4):461
Recalls & Warnings July 24, 2006 Marketers of Seasilver Ordered to Pay Almost $120 Million On July 24, 2006, the Federal Trade Commission (FTC) announced that the marketers of Seasilver, an alleged phony cure-all, have been ordered to pay almost $120 million for failing to comply with an earlier order requiring them to pay $3 million in consumer redress
average 15-17% body weight loss in trials Tirzepatide (Zepbound/Mounjaro) targets GLP-1 + GIP receptors
Infographic Brief 5 Placement: Regulatory Status, Evidence Gaps, and Clinician Discussion Points Title: Retatrutide Regulatory Status Map Purpose: Show why investigational status, FDA approval, compounding restrictions, and clinician discussion matter for interpreting retatrutide information
When a vendor cannot or will not accept standard payment methods, it typically means payment processors have already identified them as high-risk and cut them off
No measuring